Benvenue Medical, a developer of minimally invasive solutions for spine repair, completed a $60 million round of financing. The company intends to use the proceeds to accelerate U.S. commercialization activities for its two innovative minimally invasive products – the Luna 3D Interbody Fusion System for treating degenerative disc disease and the Kiva VCF Treatment System for treating vertebral compression fractures (VCFs).

The financing is a combination of $23 million in equity supplemented with $37 million in debt. The equity financing was provided by DeNovo Ventures, Domain Associates, Esquilime Partners, InterWest Partners, Technology Partners and Versant Ventures. CRG, a healthcare focused investment management firm, is the sole debt provider and also participated in the equity financing.

Santa Clara, CA-based Benvenue Medical provides next generation minimally invasive systems for spine repair that combine expandable implants with novel delivery instruments to provide enduring functional benefits for patients.